Pharmiweb.com RSS Feeds 
PharmiWeb Candidate Blog
Features
14 Dec 05
Together, the four major cancer markets, which include colorectal, prostate, lung and breast cancer, were valued at well over $16 billion in 2005, which was an increase of 14 percent in value since 2004. Driving this growth are innovative new products, line extensions for existing products, and the coming of age of the biotech industry.
Arrowhead Publishers
.jpg)
06 Dec 05
Personality tests are commonly at interviews to calculate your personality "Type". It is likely that you will be faced with one during your career.
Martin Gibbons
30 Nov 05
Dronedarone, a new Class III multi-channel blocking anti-arrhythmic drug currently in Phase III development by Sanofi-Aventis for the prevention of atrial fibrillation (AF) and atrial flutter (AFL) may help fill the unmet need for a safe pharmacologic treatment that effectively controls atrial fibrillation, cardiologists said this month. Sanofi-Aventis presented new data on dronedarone at the American Heart Association’s (AHA) annual scientific sessions held in Dallas.
Olwen Glynn Owen - PharmiWeb Field Reporter
30 Nov 05
Patients who could benefit from injectable therapies are a lot less needle-phobic than doctors assume, according to research conducted by pharmacist and behavioural scientist Professor Robert Horne. The “Open Mind” study presented at the 10th European AIDS Conference/EACS in Dublin showed over three quarters of patients would be willing to accept self-administered subcutaneous injectable therapy if offered.
Olwen Glynn Owen - PharmiWeb Field Reporter
.gif)
28 Nov 05
The two peroxisome proliferator-activated receptor (PPAR) gamma agonists pioglitazone and rosiglitazone approved for treatment of type 2 diabetes achieved combined 2004 global sales of US$ 3.96 bln shared between Takeda & Eli Lilly (52 %) and GlaxoSmithKline (48 %).
La Merie Business Intelligence
22 Nov 05
Caution: Your CV is your personal data. My advice as a recruiter, with many years experience in the clinical research industry, would be to take care where you send your CV and make sure your data is treated with the respect it deserves! The important thing is to be selective.
Linda Eden-Ellis
.gif)
14 Nov 05
Ten years after the first approval of a recombinant human FSH for treatment of infertility the US$ 0.9 bln global market of recombinant human FSH (rhFSH) in 2004 was shared between Serono (63 % for follitropin alfa) and Organon (37 % for follitropin beta).
La Merie Business Intelligence
14 Nov 05
Due to increasing interest and requests regrding the subject Pharmiweb have created a new Avian Flu resource page.
Mike Wood
11 Nov 05
Due to demand, we at PharmiWeb have added a new Executive Jobs Listing to our comprehensive careers section. All these jobs include packages of over ÂŁ100K (GBP) per year.
Mike Wood
31 Oct 05
For those new to the industry, a quick round up of the common abbreviations and what they stand for might be useful....
Spencer Marsh
.gif)
31 Oct 05
Patent expiry of recombinant tissue-type plasminogen activator (t-PA) and its TNK-derivative commencing in 2005 did not lead to biogeneric competition in regulated markets.
La Merie Business Intelligence
24 Oct 05
Complete our user survey and you could win a ÂŁ25 Amazon voucher!
Mike Wood
.gif)
24 Oct 05
After Genentech had to terminate commercializtion of its Nutropin Depot preparation, the field now is lead by Korea-based LG Life Science and its European licensee BioPartners with the slow release formulation of hGH (LB03002)
La Merie Business Intelligence Press Release
17 Oct 05
More than 20 additional companies with activites in the biogeneric field of G-CSF were identified in a search conducted by La Merie Business Intelligence.
La Merie Business Intelligence PR
13 Oct 05
Biotechnology is seen as a key technology area for the future and like many other countries, South Africa is keen to develop its expertise in this field. The emphasis on biotechnology is certainly influenced to a large degree by the outstanding success of the US biotech industry – an economic feat that most other countries would like to emulate.
Britt Akermann and Dr Faiz Kermani
.jpg)
13 Oct 05
The prevalence of diabetes, in particular type 2 diabetes, is increasing worldwide. Type 2 diabetes increases with age, but recently has been affecting much younger individuals. In the UK, diabetes prevalence has doubled over the last 12-15 years, and is set to double again over a similar timeframe. The prevalence of diabetes in the UK is now, on average, 3.3%, though many patients are undiagnosed.
CSF Medical
10 Oct 05
The Business Intelligence firm La Merie S.L. recently analyzed the pipeline of thrombopoietin-stimulating agents. Main outcome of the search was that only two recombinant macromolecular proteins of the many projects initiated in the last decade are left.
Jorge Márquez
29 Sep 05
On Wednesday 22nd June, PharmiWeb Solutions and Microsoft brought together a senior group of sales and marketing professionals, to discuss how software and e-business based solutions can deliver competitive advantage for the pharmaceutical organisation.
Colin Williams
23 Sep 05
Pharma Sales World 2005 will provide delegates with a unique opportunity to gain critical business information about how Europe’s leading pharma companies are addressing the challenge of improving sales force effectiveness. The conference will highlight the issues of accessibility, emerging customer bases, market changes in the next decade, sales force size and structure, targeting and segmentation, the new breed of representative, data acquisition, training and development, customer relationshi
Hannah Reading
.jpg)
23 Sep 05
Fractures resulting from osteoporosis are widely recognised as a major cause of morbidity and mortality in the elderly population. It has been estimated that approximately 310,000 osteoporotic fractures occur annually in the UK, with a consequent cost to the health service of ÂŁ1.7 billion.
CSF Medical
20 Sep 05
On Friday 16th September, before a glittering audience of local business Champions, Exco was awarded the highly acclaimed prize of Small Business of the Year 2005.
Sarah Eadon
06 Sep 05
The pharmaceutical industry’s new molecular entity (NME) submissions to the U.S. FDA and new active substance (NAS) submissions to the European Medicines Evaluation Agency (EMEA) rose to five-year highs in 2004, according to PAREXEL’s Pharmaceutical R&D Statistical Sourcebook 2005/2006.
http://www.barnettinternational.com
.jpg)
05 Sep 05
Epilepsy is characterised by a tendency to experience unprovoked seizures and is one of the most common neurological disorders. Over 2% of the population will experience a seizure at some time in their life, and recurrent unprovoked seizures will require treatment in approximately one-in-200 people at any given time. Treatment of epilepsy remains important in helping to reduce the psychological and social sequelae which follow on from uncontrolled seizures.
CSF Medical
.jpg)
22 Aug 05
It is often forgotten that until the late 1950s there was no treatment for schizophrenia, or for that matter, any other severe enduring mental illness. The majority of patients admitted to asylum care never left: hence the peak occupancy of 150,000 reported in the UK in 1955. As an interesting comparison, this is twice the current UK prison population.
CSF Medical
18 Aug 05
According to LeadDiscovery's recent feature report, Pain Therapeutics 2005, about one and a half billion people suffer from moderate to severe chronic pain worldwide, driving the market for analgesics to nearly $23 billion in 2004. Many companies are investing heavily in the development of new pain therapeutics, even more so now with the recent problems to have hit the Cox-II inhibitors. Calcium channel blockers stepped into the spotlight at the end of last year with the FDA approval of Elan's Z
LeadDiscovery
18 Aug 05
Worth an estimated $35 billion in 2003, analysts predict that the sale of oncology therapeutics will grow to $60 billion by 2010. Targeted therapeutics represent one of the most exciting new developments in the field of oncology and include angiogenesis inhibitors; apoptosis stimulators and; signal transduction inhibitors. Apoptosis stimulators lead by Genta's Genesense are particularly appealing. Canadian researchers are focusing on a stimulator of apoptosis known as pancratistatin. This molecu
LeadDiscovery
18 Aug 05
Parkinson's disease drug revenues grew an impressive 17% across the seven major markets to reach $1.7 billion in 2003. Despite the commercial success associated with this therapy area, currently available treatments focus on levodopa which replaces the loss of striatal dopamine, the hall mark of Parkinson's disease, rather than targeting disease progression. The efficacy of levodopa eventually declines in most patients and new therapies with disease modifying activity are urgently required. A gr
LeadDiscovery
18 Aug 05
Hypertension continues to represent a highly prevalent clinical problem affecting 190 million people in the 7 major pharmaceutical markets. This therapeutic area is also a highly lucrative field for pharmaceutical companies with sales exceeding $30 billion in 2003. Despite the improved efficacy and tolerability of the angiotensin receptor blocker class led by valsartan, physicians remain frustrated by the lack of efficacy of antihypertensive agents and the current trend is towards the use of com
LeadDiscovery
18 Aug 05
Earlier in 2005, LeadDiscovery published an in depth report on the development of the novel anti-cancer class, the HDAC inhibitors. As this class advances with therapeutic candidates now entering phase II trials, companies are seeking to optimize therapeutic margins by targeting specific isoforms of histone deacetylase that are involved in tumor progression. In a recent NEJM study Prof. Peter Barnes and colleagues demonstrates that the inhibition of HDAC2 could introduce airway risks, possibly e
LeadDiscovery
18 Aug 05
The overlapping fields of angiogenesis and growth factor biology represent two extensively investigated areas of modern day oncology and the recent success of Avastin, a monoclonal antibody that binds to and neutralizes one such growth factor, VEGF has not only resulted in the introduction of an effective clinical tool for the treatment of cancer but it also helped spark a wave of optimism in the angiogenesis inhibitor arena. As a result companies are evaluating new approaches to target VEGF in
LeadDiscovery
